PL3289355T3 - Sposoby wykrywania chorób nerek - Google Patents
Sposoby wykrywania chorób nerekInfo
- Publication number
- PL3289355T3 PL3289355T3 PL16787315.7T PL16787315T PL3289355T3 PL 3289355 T3 PL3289355 T3 PL 3289355T3 PL 16787315 T PL16787315 T PL 16787315T PL 3289355 T3 PL3289355 T3 PL 3289355T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- renal disease
- detecting renal
- detecting
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155158P | 2015-04-30 | 2015-04-30 | |
| PCT/US2016/030478 WO2016176691A1 (en) | 2015-04-30 | 2016-05-02 | Methods for detecting renal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3289355T3 true PL3289355T3 (pl) | 2025-11-24 |
Family
ID=57199396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16787315.7T PL3289355T3 (pl) | 2015-04-30 | 2016-05-02 | Sposoby wykrywania chorób nerek |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20180120326A1 (pl) |
| EP (2) | EP3289355B1 (pl) |
| JP (2) | JP6923449B2 (pl) |
| AU (1) | AU2016254226C1 (pl) |
| CA (1) | CA2983943A1 (pl) |
| ES (1) | ES3041077T3 (pl) |
| MX (2) | MX2017013728A (pl) |
| PL (1) | PL3289355T3 (pl) |
| PT (1) | PT3289355T (pl) |
| WO (1) | WO2016176691A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745492B1 (en) * | 2019-04-03 | 2020-08-18 | Ark Diagnostics, Inc. | Antibodies to symmetrically dimethylated arginine analytes and use thereof |
| EP4022089B1 (en) * | 2019-12-18 | 2024-08-21 | Hill's Pet Nutrition, Inc. | Methods for identifying a companion animal at risk of calcium oxalate stone formation and medical uses for reducing the risk |
| WO2024135740A1 (ja) * | 2022-12-21 | 2024-06-27 | 花王株式会社 | 猫の腎機能障害の検査方法 |
| WO2025205769A1 (ja) * | 2024-03-26 | 2025-10-02 | 富士フイルム株式会社 | α-アミラーゼと対称性ジメチルアルギニンとのコンジュゲート、およびその応用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818703A (en) | 1985-10-23 | 1989-04-04 | Pizzolante John M | Stabilized alkaline picrate reagent for jaffe creatinine determination |
| US5726010A (en) | 1991-07-31 | 1998-03-10 | Idexx Laboratories, Inc. | Reversible flow chromatographic binding assay |
| EP1056770A1 (en) * | 1998-02-24 | 2000-12-06 | Dovetail Technologies, Inc. | Novel disulfides and thiol compounds |
| CA2399169A1 (en) * | 2001-09-07 | 2003-03-07 | Queen's University At Kingston | Diagnostic methods for determining susceptibility to convulsive conditions |
| JP4214271B2 (ja) | 2002-10-15 | 2009-01-28 | アークレイ株式会社 | クレアチニン測定用試験片 |
| JP4929635B2 (ja) * | 2005-07-14 | 2012-05-09 | 富士ゼロックス株式会社 | マレイミド基含有多孔質架橋ポリスチレン粒子及びその製造方法 |
| DE102005051976B4 (de) * | 2005-10-31 | 2009-04-30 | Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften | Kit für hoch-sensitive Nachweisassays |
| US8481690B2 (en) | 2008-08-07 | 2013-07-09 | Idexx Laboratories, Inc. | Methods for detecting symmetrical dimethylarginine |
| US20120129265A1 (en) * | 2009-06-02 | 2012-05-24 | Biocrates Life Sciences Ag | New biomarkers for assessing kidney diseases |
| WO2011130385A1 (en) * | 2010-04-13 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Biomarkers for hepatocellular cancer |
| WO2012096893A2 (en) * | 2011-01-10 | 2012-07-19 | Opko Pharmaceuticals, Llc | Antigen surrogates in autoimmune disease |
| EP2788763A4 (en) * | 2011-12-09 | 2015-10-07 | Metabolon Inc | BIOMARKERS FOR RENAL CANCER AND METHODS OF USE |
| WO2013115283A1 (ja) * | 2012-01-31 | 2013-08-08 | 味の素株式会社 | 早期腎症の評価方法、早期腎症評価装置、早期腎症評価方法、早期腎症評価プログラム、早期腎症評価システムおよび情報通信端末装置 |
| CN104903302B (zh) * | 2012-11-21 | 2019-03-29 | 阿奇克斯制药公司 | 大环广谱抗生素 |
| RS59287B1 (sr) * | 2013-09-05 | 2019-10-31 | Idexx Lab Inc | Postupci za otkrivanje bolesti bubrega |
| CN105492034A (zh) | 2013-09-05 | 2016-04-13 | 生命细胞公司 | 用于组织产物的酶处理的方法 |
-
2016
- 2016-05-02 US US15/569,619 patent/US20180120326A1/en not_active Abandoned
- 2016-05-02 PL PL16787315.7T patent/PL3289355T3/pl unknown
- 2016-05-02 CA CA2983943A patent/CA2983943A1/en active Pending
- 2016-05-02 AU AU2016254226A patent/AU2016254226C1/en active Active
- 2016-05-02 EP EP16787315.7A patent/EP3289355B1/en active Active
- 2016-05-02 WO PCT/US2016/030478 patent/WO2016176691A1/en not_active Ceased
- 2016-05-02 EP EP25186589.5A patent/EP4640716A2/en active Pending
- 2016-05-02 PT PT167873157T patent/PT3289355T/pt unknown
- 2016-05-02 JP JP2017556244A patent/JP6923449B2/ja active Active
- 2016-05-02 ES ES16787315T patent/ES3041077T3/es active Active
- 2016-05-02 MX MX2017013728A patent/MX2017013728A/es unknown
-
2017
- 2017-10-25 MX MX2023007778A patent/MX2023007778A/es unknown
-
2021
- 2021-03-01 US US17/188,710 patent/US20210239704A1/en not_active Abandoned
- 2021-07-29 JP JP2021123796A patent/JP7282132B2/ja active Active
-
2025
- 2025-01-08 US US19/013,094 patent/US20250147034A1/en active Pending
- 2025-01-08 US US19/013,056 patent/US20250147033A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016176691A1 (en) | 2016-11-03 |
| CA2983943A1 (en) | 2016-11-03 |
| MX2023007778A (es) | 2023-07-10 |
| US20250147034A1 (en) | 2025-05-08 |
| EP3289355A1 (en) | 2018-03-07 |
| PT3289355T (pt) | 2025-09-12 |
| US20210239704A1 (en) | 2021-08-05 |
| AU2016254226A1 (en) | 2017-11-09 |
| EP3289355B1 (en) | 2025-07-02 |
| AU2016254226B2 (en) | 2022-05-26 |
| JP2018515761A (ja) | 2018-06-14 |
| JP6923449B2 (ja) | 2021-08-18 |
| EP4640716A2 (en) | 2025-10-29 |
| JP7282132B2 (ja) | 2023-05-26 |
| US20180120326A1 (en) | 2018-05-03 |
| ES3041077T3 (en) | 2025-11-07 |
| EP3289355A4 (en) | 2019-02-13 |
| JP2021181994A (ja) | 2021-11-25 |
| US20250147033A1 (en) | 2025-05-08 |
| AU2016254226C1 (en) | 2022-11-24 |
| MX2017013728A (es) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3294906T3 (en) | Methods for determining ploidy | |
| GB2547152B (en) | Rider Detection System | |
| IL269613A (en) | Methods for defining renal function | |
| ZA201605660B (en) | Multispecific antibodies | |
| PL3227332T3 (pl) | Wielospecyficzne przeciwciała | |
| SMT201900526T1 (it) | Metodi per rilevare una malattia renale | |
| ZA201504861B (en) | Apparatus for improved disease detection | |
| GB201414823D0 (en) | Multispecific antibodies | |
| HUE056054T2 (hu) | Eljárások foszforilezett alfa-szinuklein kimutatására | |
| SG11201706686YA (en) | Methods for determining resist deformation | |
| IL256198A (en) | Biomarkers for disease states for kidney disease | |
| IL259904A (en) | Multiple threat detection system | |
| PT3289355T (pt) | Métodos para detetar doença renal | |
| EP3217173A4 (en) | Method for detecting disease | |
| SG11201610359QA (en) | Method for determining a protein-protein interaction | |
| EP3173791A4 (en) | Method for determining pancreatic disease | |
| GB201400091D0 (en) | Sorbent for halogen compounds | |
| IL250288A0 (en) | A method for analyzing information technology infrastructure use problems | |
| IL252363A0 (en) | A system for detecting molecules | |
| IL247996B (en) | A method for detecting changes in proteins | |
| GB201502226D0 (en) | AH-7921 detection | |
| GB201513981D0 (en) | Acaricides | |
| GB201509756D0 (en) | D-N-A-cure for every disease | |
| GB201604813D0 (en) | Methods for detecting cancer | |
| SG11201704105SA (en) | Renal function improving agent |